{"name":"Novo A/S","permalink":"novo-a-s","crunchbase_url":"http://www.crunchbase.com/financial-organization/novo-a-s","homepage_url":"http://www.novo.dk/","blog_url":"","blog_feed_url":"","twitter_username":null,"phone_number":"","description":"","email_address":"","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"tag_list":"","alias_list":null,"created_at":"Fri Apr 10 14:30:01 UTC 2009","updated_at":"Tue Apr 28 15:24:48 UTC 2009","overview":"<p>Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation.\nNovo A/S is the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.\nNovo A/Sâ€™ objective is to manage the Foundationâ€™s financial assets through investments in the life science area and in a broad portfolio of financial assets.</p>","image":null,"offices":[],"relationships":[{"is_past":false,"title":"Partner","person":{"first_name":"Jack","last_name":"Nielson","permalink":"jack-nielson","image":null}}],"investments":[{"funding_round":{"round_code":"c","source_url":"http://www.pehub.com/?p=36872","source_description":"Cell Biosciences Raises $10 Million","raised_amount":10000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":4,"funded_day":10,"company":{"name":"ProteinSimple","permalink":"cell-biosciences","image":{"available_sizes":[[[150,39],"assets/images/resized/0004/0799/40799v3-max-150x150.jpg"],[[171,45],"assets/images/resized/0004/0799/40799v3-max-250x250.jpg"],[[171,45],"assets/images/resized/0004/0799/40799v3-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://deals.venturebeat.com/2007/01/05/neurological-co-synosis-raises-325m/","source_description":"Neurological co. Synosis raises $32.5M","raised_amount":32500000,"raised_currency_code":"USD","funded_year":2007,"funded_month":1,"funded_day":5,"company":{"name":"Synosia Therapeutics","permalink":"synosia-therapeutics","image":{"available_sizes":[[[150,49],"assets/images/resized/0004/3264/43264v1-max-150x150.png"],[[217,71],"assets/images/resized/0004/3264/43264v1-max-250x250.png"],[[217,71],"assets/images/resized/0004/3264/43264v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://venturebeat.com/2009/10/19/lux-biosciences-scores-50m-series-b-for-eye-cure/","source_description":"Lux Biosciences scores $50M Series B for eye cure","raised_amount":50000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":10,"funded_day":null,"company":{"name":"Lux Biosciences","permalink":"lux-biosciences","image":{"available_sizes":[[[123,82],"assets/images/resized/0006/3157/63157v1-max-150x150.jpg"],[[123,82],"assets/images/resized/0006/3157/63157v1-max-250x250.jpg"],[[123,82],"assets/images/resized/0006/3157/63157v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.finsmes.com/2009/12/cell-biosciences-raises-4m-and-acquires.html","source_description":"Cell Biosciences Raises $4M and Acquires Protein Forest","raised_amount":4000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":12,"funded_day":7,"company":{"name":"ProteinSimple","permalink":"cell-biosciences","image":{"available_sizes":[[[150,39],"assets/images/resized/0004/0799/40799v3-max-150x150.jpg"],[[171,45],"assets/images/resized/0004/0799/40799v3-max-250x250.jpg"],[[171,45],"assets/images/resized/0004/0799/40799v3-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.fiercebiotech.com/story/ophthotech-nabs-30m-round-fund-amd-trial/2009-12-15?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0","source_description":"Ophthotech nabs $30M round to fund AMD trial","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":12,"funded_day":15,"company":{"name":"Ophthotech","permalink":"ophthotech","image":{"available_sizes":[[[150,25],"assets/images/resized/0006/9859/69859v1-max-150x150.jpg"],[[250,42],"assets/images/resized/0006/9859/69859v1-max-250x250.jpg"],[[368,62],"assets/images/resized/0006/9859/69859v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"e","source_url":"http://www.finsmes.com/2009/12/ptc-therapeutics-raises-50m-in-equity.html","source_description":"PTC Therapeutics Raises 50M in Equity Financing","raised_amount":50000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":12,"funded_day":22,"company":{"name":"PTC Therapeutics","permalink":"ptc-therapeutics","image":{"available_sizes":[[[150,69],"assets/images/resized/0006/8365/68365v1-max-150x150.jpg"],[[208,97],"assets/images/resized/0006/8365/68365v1-max-250x250.jpg"],[[208,97],"assets/images/resized/0006/8365/68365v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.anaptysbio.com/index.php?doc_id=15","source_description":"AnaptysBio raises over $33 million in Series B financing","raised_amount":33000000,"raised_currency_code":"USD","funded_year":2007,"funded_month":11,"funded_day":8,"company":{"name":"AnaptysBio","permalink":"anaptysbio","image":{"available_sizes":[[[150,47],"assets/images/resized/0007/9970/79970v1-max-150x150.jpg"],[[250,79],"assets/images/resized/0007/9970/79970v1-max-250x250.jpg"],[[271,86],"assets/images/resized/0007/9970/79970v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://onbiovc.com/archimedes-pharma-ltd-series-c-99m/","source_description":"Archimedes Pharma, Ltd.: Series C $99M ","raised_amount":99000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":4,"funded_day":5,"company":{"name":"Archimedes Pharma","permalink":"archimedes-pharma","image":{"available_sizes":[[[150,51],"assets/images/resized/0007/8870/78870v1-max-150x150.jpg"],[[220,75],"assets/images/resized/0007/8870/78870v1-max-250x250.jpg"],[[220,75],"assets/images/resized/0007/8870/78870v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.fiercebiotech.com/story/glaucoma-drug-focus-inspires-20m-round-altheos/2010-04-05","source_description":"Glaucoma drug focus inspires $20M A round for Altheos","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":4,"funded_day":5,"company":{"name":"Altheos","permalink":"altheos","image":{"available_sizes":[[[117,60],"assets/images/resized/0008/2971/82971v1-max-150x150.jpg"],[[117,60],"assets/images/resized/0008/2971/82971v1-max-250x250.jpg"],[[117,60],"assets/images/resized/0008/2971/82971v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"d","source_url":"http://bulletin.sciencebusiness.net/sb/login.php?page=/ebulletins/showissue.php3?page=/548/art/4700","source_description":"Symphogen gets $25M for clinical trials for bleeding treatment","raised_amount":25000000,"raised_currency_code":"USD","funded_year":2006,"funded_month":1,"funded_day":10,"company":{"name":"Symphogen","permalink":"symphogen","image":{"available_sizes":[[[150,61],"assets/images/resized/0004/1671/41671v1-max-150x150.png"],[[194,79],"assets/images/resized/0004/1671/41671v1-max-250x250.png"],[[194,79],"assets/images/resized/0004/1671/41671v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://mqti.com/news.cfm?aId=9BE32D3E-C298-58F6-0811FC69330C62A6","source_description":"MediQuest Therapeutics Raises $16.0 Million In Series A Financing","raised_amount":16000000,"raised_currency_code":"USD","funded_year":2006,"funded_month":6,"funded_day":15,"company":{"name":"MediQuest Therapeutics","permalink":"mediquest-therapeutics","image":{"available_sizes":[[[150,30],"assets/images/resized/0004/8847/48847v1-max-150x150.png"],[[250,50],"assets/images/resized/0004/8847/48847v1-max-250x250.png"],[[359,73],"assets/images/resized/0004/8847/48847v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.celltrix.se/Portals/4/docs/4majpressrelease1.pdf","source_description":"New owners invest in Celltrix technology","raised_amount":3000000,"raised_currency_code":"EUR","funded_year":2006,"funded_month":5,"funded_day":16,"company":{"name":"Celltrix","permalink":"celltrix","image":{"available_sizes":[[[150,44],"assets/images/resized/0008/5155/85155v1-max-150x150.jpg"],[[159,47],"assets/images/resized/0008/5155/85155v1-max-250x250.jpg"],[[159,47],"assets/images/resized/0008/5155/85155v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://www.fiercebiotech.com/story/logical-therapeutics-closes-16-9m-round-nsaid-program/2010-05-27?utm_medium=rss&utm_source=rss","source_description":"Logical Therapeutics closes $16.9M round for NSAID program","raised_amount":16900000,"raised_currency_code":"USD","funded_year":2010,"funded_month":5,"funded_day":27,"company":{"name":"Logical Therapeutics","permalink":"logical-therapeutics","image":{"available_sizes":[[[150,33],"assets/images/resized/0008/8366/88366v1-max-150x150.jpg"],[[250,55],"assets/images/resized/0008/8366/88366v1-max-250x250.jpg"],[[354,79],"assets/images/resized/0008/8366/88366v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.lsoncology.com/press_releases/release/pr_1206666394","source_description":"LIGHT SCIENCES ONCOLOGY COMPLETES SECOND CLOSING IN $67 MILLION FINANCING FOR LATE STAGE DEVELOPMENT OF LITXâ„¢ AND ANNOUNCES ADDITIONAL DIRECTORS","raised_amount":67000000,"raised_currency_code":"USD","funded_year":2005,"funded_month":12,"funded_day":14,"company":{"name":"Light Sciences Oncology","permalink":"light-sciences-oncology","image":{"available_sizes":[[[150,39],"assets/images/resized/0006/5310/65310v1-max-150x150.png"],[[244,65],"assets/images/resized/0006/5310/65310v1-max-250x250.png"],[[244,65],"assets/images/resized/0006/5310/65310v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://ptct.client.shareholder.com/releasedetail.cfm?ReleaseID=197021","source_description":"PTC THERAPEUTICS RAISES $26.6 MILLION IN PRIVATE PLACEMENT FINANCING","raised_amount":26600000,"raised_currency_code":"USD","funded_year":2005,"funded_month":11,"funded_day":10,"company":{"name":"PTC Therapeutics","permalink":"ptc-therapeutics","image":{"available_sizes":[[[150,69],"assets/images/resized/0006/8365/68365v1-max-150x150.jpg"],[[208,97],"assets/images/resized/0006/8365/68365v1-max-250x250.jpg"],[[208,97],"assets/images/resized/0006/8365/68365v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"","source_description":"Cap funding Report","raised_amount":null,"raised_currency_code":"USD","funded_year":2010,"funded_month":5,"funded_day":25,"company":{"name":"Nanoference","permalink":"nanoference","image":null}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.reatapharma.com/news_detail.asp?id=62","source_description":"Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methy","raised_amount":78000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":7,"funded_day":12,"company":{"name":"Reata Pharmaceuticals","permalink":"reata-pharmaceuticals","image":{"available_sizes":[[[101,74],"assets/images/resized/0009/3101/93101v2-max-150x150.png"],[[101,74],"assets/images/resized/0009/3101/93101v2-max-250x250.png"],[[101,74],"assets/images/resized/0009/3101/93101v2-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.tobiratherapeutics.com/pdfs/Tobira_Therapeutics_Series.pdf","source_description":"Tobira Therapeutics Inc. Raises $31 Million in Series B Financing","raised_amount":31000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":9,"funded_day":29,"company":{"name":"Tobira Therapeutics","permalink":"tobira-therapeutics","image":{"available_sizes":[[[149,105],"assets/images/resized/0010/3787/103787v1-max-150x150.jpg"],[[149,105],"assets/images/resized/0010/3787/103787v1-max-250x250.jpg"],[[149,105],"assets/images/resized/0010/3787/103787v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://www.synosia.com/list-details.aspx?listguid=E8469572-06DC-475F-9815-2A91E1232F9A&folderguid=801EEB72-27A8-495F-8A19-242E20F5F875","source_description":"Synosia Therapeutics Raises $30M in Series C Financing","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":10,"funded_day":12,"company":{"name":"Synosia Therapeutics","permalink":"synosia-therapeutics","image":{"available_sizes":[[[150,49],"assets/images/resized/0004/3264/43264v1-max-150x150.png"],[[217,71],"assets/images/resized/0004/3264/43264v1-max-250x250.png"],[[217,71],"assets/images/resized/0004/3264/43264v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"f","source_url":"http://www.xconomy.com/san-francisco/2010/10/14/cell-biosciences-nabs-20m-buys-convergent/","source_description":"Cell Biosciences Nabs $20M","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":10,"funded_day":14,"company":{"name":"ProteinSimple","permalink":"cell-biosciences","image":{"available_sizes":[[[150,39],"assets/images/resized/0004/0799/40799v3-max-150x150.jpg"],[[171,45],"assets/images/resized/0004/0799/40799v3-max-250x250.jpg"],[[171,45],"assets/images/resized/0004/0799/40799v3-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.finsmes.com/2011/01/symphogen-closes-100m-round-of.html","source_description":"Symphogen Closes â‚¬100M Round of Financing","raised_amount":100000000,"raised_currency_code":"EUR","funded_year":2011,"funded_month":1,"funded_day":6,"company":{"name":"Symphogen","permalink":"symphogen","image":{"available_sizes":[[[150,61],"assets/images/resized/0004/1671/41671v1-max-150x150.png"],[[194,79],"assets/images/resized/0004/1671/41671v1-max-250x250.png"],[[194,79],"assets/images/resized/0004/1671/41671v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"f","source_url":"http://onbiovc.com/symphogen-as-series-f-1354m/","source_description":"Symphogen, AS: Series F $135.4M","raised_amount":135400000,"raised_currency_code":"USD","funded_year":2011,"funded_month":2,"funded_day":14,"company":{"name":"Symphogen","permalink":"symphogen","image":{"available_sizes":[[[150,61],"assets/images/resized/0004/1671/41671v1-max-150x150.png"],[[194,79],"assets/images/resized/0004/1671/41671v1-max-250x250.png"],[[194,79],"assets/images/resized/0004/1671/41671v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"d","source_url":"http://www.htgenomics.com/htg-completes-first-tranche-of-157-million-series-d-financing-628.htm","source_description":"HTG Completes First Tranche of $15.7 Million Series D Financing","raised_amount":15700000,"raised_currency_code":"USD","funded_year":2011,"funded_month":2,"funded_day":23,"company":{"name":"High Throughput Genomics","permalink":"high-throughput-genomics","image":{"available_sizes":[[[150,86],"assets/images/resized/0012/3897/123897v1-max-150x150.jpg"],[[154,89],"assets/images/resized/0012/3897/123897v1-max-250x250.jpg"],[[154,89],"assets/images/resized/0012/3897/123897v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"seed","source_url":"http://www.orphazyme.com/news","source_description":"Orphazyme raises 22 mDKK in a seed round extension; Sunstone Capital joins as new investor ","raised_amount":null,"raised_currency_code":"USD","funded_year":2011,"funded_month":2,"funded_day":14,"company":{"name":"Orphazyme","permalink":"orphazyme","image":{"available_sizes":[[[150,31],"assets/images/resized/0012/8021/128021v1-max-150x150.png"],[[250,51],"assets/images/resized/0012/8021/128021v1-max-250x250.png"],[[386,80],"assets/images/resized/0012/8021/128021v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"d","source_url":"http://www.finsmes.com/2011/06/htg-molecular-diagnostics-receives-500k-sr-series-financing.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29","source_description":"HTG Molecular Diagnostics Receives $500k from SR One in Series D Financing","raised_amount":15700000,"raised_currency_code":"USD","funded_year":2011,"funded_month":2,"funded_day":24,"company":{"name":"HTG Molecular Diagnostics","permalink":"htg-molecular-diagnostics","image":{"available_sizes":[[[150,89],"assets/images/resized/0013/8983/138983v1-max-150x150.jpg"],[[150,89],"assets/images/resized/0013/8983/138983v1-max-250x250.jpg"],[[150,89],"assets/images/resized/0013/8983/138983v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.vantiatherapeutics.com/news/news/vantia_pr_060711.pdf","source_description":"Vantia Therapeutics Raises Â£4 Million to Fund Clinical Development of its Lead Compounds","raised_amount":6500000,"raised_currency_code":"USD","funded_year":2011,"funded_month":7,"funded_day":6,"company":{"name":"Vantia Therapeutics","permalink":"vantia-therapeutics","image":{"available_sizes":[[[150,59],"assets/images/resized/0014/2809/142809v1-max-150x150.png"],[[247,98],"assets/images/resized/0014/2809/142809v1-max-250x250.png"],[[247,98],"assets/images/resized/0014/2809/142809v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.f-star.com/press_releases/f-star_SerA_Second_281107.pdf","source_description":"Antibody Engineering Company F-Star Raises EUR 3.0 million in a Second Closing of its Series A Financing Round from Novo A/S","raised_amount":3000000,"raised_currency_code":"EUR","funded_year":2007,"funded_month":11,"funded_day":28,"company":{"name":"f-star Biotech","permalink":"f-star-biotechnologische-forschungs-und-entwicklungsges-m-b-h","image":{"available_sizes":[[[148,150],"assets/images/resized/0007/2453/72453v1-max-150x150.jpg"],[[148,150],"assets/images/resized/0007/2453/72453v1-max-250x250.jpg"],[[148,150],"assets/images/resized/0007/2453/72453v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.prnewswire.com/news-releases/kalvista-pharmaceuticals-launched-with-8-million-in-series-a-funding-to-develop-novel-class-of-drugs-for-diabetic-macular-edema-128230123.html","source_description":"KalVista Pharmaceuticals Launched With Â£8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema","raised_amount":8000000,"raised_currency_code":"GBP","funded_year":2011,"funded_month":8,"funded_day":23,"company":{"name":"KalVista Pharmaceuticals","permalink":"kalvista-pharmaceuticals","image":{"available_sizes":[[[150,132],"assets/images/resized/0015/0686/150686v1-max-150x150.jpg"],[[187,165],"assets/images/resized/0015/0686/150686v1-max-250x250.jpg"],[[187,165],"assets/images/resized/0015/0686/150686v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.fiercebiotech.com/story/orphazyme-lands-20m-round-back-new-drugs-rare-genetic-disorder/2011-09-07?utm_medium=rss&utm_source=rss","source_description":"Orphazyme lands $20M A round to back new drugs for rare genetic disorder","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":9,"funded_day":7,"company":{"name":"Orphazyme","permalink":"orphazyme","image":{"available_sizes":[[[150,31],"assets/images/resized/0012/8021/128021v1-max-150x150.png"],[[250,51],"assets/images/resized/0012/8021/128021v1-max-250x250.png"],[[386,80],"assets/images/resized/0012/8021/128021v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.fiercebiotech.com/story/altheos-grabs-125m-more-launches-glaucoma-trial/2012-02-09?utm_medium=rss&utm_source=rss","source_description":"Altheos grabs $12.5M more, launches glaucoma trial ","raised_amount":12500000,"raised_currency_code":"USD","funded_year":2012,"funded_month":2,"funded_day":9,"company":{"name":"Altheos","permalink":"altheos","image":{"available_sizes":[[[117,60],"assets/images/resized/0008/2971/82971v1-max-150x150.jpg"],[[117,60],"assets/images/resized/0008/2971/82971v1-max-250x250.jpg"],[[117,60],"assets/images/resized/0008/2971/82971v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.prnewswire.com/news-releases/tarsa-therapeutics-completes-28-million-series-b-financing-to-advance-ostora-oral-calcitonin-142908965.html","source_description":"Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin","raised_amount":28000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":3,"funded_day":16,"company":{"name":"Tarsa Therapeutics","permalink":"tarsa-therapeutics","image":{"available_sizes":[[[150,80],"assets/images/resized/0007/4051/74051v1-max-150x150.jpg"],[[250,134],"assets/images/resized/0007/4051/74051v1-max-250x250.jpg"],[[345,186],"assets/images/resized/0007/4051/74051v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.masshightech.com/stories/2012/04/02/daily4-AlloCure-raises-25M-round-for-kidney-disease-trial-.html","source_description":"AlloCure raises $25M round for kidney disease trial ","raised_amount":25000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":4,"funded_day":2,"company":{"name":"AlloCure","permalink":"allocure","image":{"available_sizes":[[[150,59],"assets/images/resized/0009/2698/92698v1-max-150x150.png"],[[250,98],"assets/images/resized/0009/2698/92698v1-max-250x250.png"],[[273,108],"assets/images/resized/0009/2698/92698v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.inogenone.com/Inogen-Secures-20-Million-in-Financing-Led-by-Novo-A-S/#.T4eUWdk2ldg","source_description":"Inogen Secures $20 Million in Financing Led by Novo A/S ","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":4,"funded_day":12,"company":{"name":"Inogen","permalink":"inogen","image":{"available_sizes":[[[150,60],"assets/images/resized/0015/0816/150816v1-max-150x150.png"],[[207,83],"assets/images/resized/0015/0816/150816v1-max-250x250.png"],[[207,83],"assets/images/resized/0015/0816/150816v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://pevc.dowjones.com/article?an=DJFVW00020120621e86lmuwqs&from=alert&pid=32&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%3a80%2farticle%3fan%3dDJFVW00020120621e86lmuwqs%26from%3dalert%26pid%3d32","source_description":"Denmark's Santaris Grabs $12M From Insiders for Clinical Trials ","raised_amount":12000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":6,"funded_day":21,"company":{"name":"Santaris Pharma","permalink":"santaris-pharma","image":{"available_sizes":[[[150,61],"assets/images/resized/0019/6720/196720v1-max-150x150.jpg"],[[161,66],"assets/images/resized/0019/6720/196720v1-max-250x250.jpg"],[[161,66],"assets/images/resized/0019/6720/196720v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.finsmes.com/2012/07/ptc-therapeutics-completes-30m-financing.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29","source_description":"PTC Therapeutics Completes $30M Financing","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":7,"funded_day":23,"company":{"name":"PTC Therapeutics","permalink":"ptc-therapeutics","image":{"available_sizes":[[[150,69],"assets/images/resized/0006/8365/68365v1-max-150x150.jpg"],[[208,97],"assets/images/resized/0006/8365/68365v1-max-250x250.jpg"],[[208,97],"assets/images/resized/0006/8365/68365v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://pevc.dowjones.com/article?an=DJFVW00020120906e896oaipx&from=alert&pid=32&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%3a80%2farticle%3fan%3dDJFVW00020120906e896oaipx%26from%3dalert%26pid%3d32","source_description":"Karus Thera Picks Up $7.6M to Develop Two Preclinical Compounds","raised_amount":7600000,"raised_currency_code":"USD","funded_year":2012,"funded_month":9,"funded_day":6,"company":{"name":"Karus Therapeutics ","permalink":"karus-therapeutics","image":{"available_sizes":[[[150,59],"assets/images/resized/0021/0236/210236v1-max-150x150.jpg"],[[250,99],"assets/images/resized/0021/0236/210236v1-max-250x250.jpg"],[[261,104],"assets/images/resized/0021/0236/210236v1-max-450x450.jpg"]],"attribution":null}}}}],"milestones":[],"providerships":[],"funds":[],"video_embeds":[],"external_links":[]}